- Home
- TAC vs DYN Comparison
TAC vs DYN Comparison
Compare TAC & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAC
- DYN
- Stock Information
- Founded
- TAC 1909
- DYN 1984
- Country
- TAC Canada
- DYN United States
- Employees
- TAC N/A
- DYN N/A
- Industry
- TAC Electric Utilities: Central
- DYN Medicinal Chemicals and Botanical Products
- Sector
- TAC Utilities
- DYN Health Care
- Exchange
- TAC Nasdaq
- DYN Nasdaq
- Market Cap
- TAC 3.1B
- DYN 2.6B
- IPO Year
- TAC N/A
- DYN 2020
- Fundamental
- Price
- TAC $14.45
- DYN $14.55
- Analyst Decision
- TAC
- DYN Strong Buy
- Analyst Count
- TAC 0
- DYN 10
- Target Price
- TAC N/A
- DYN $50.70
- AVG Volume (30 Days)
- TAC 1.4M
- DYN 1.8M
- Earning Date
- TAC 02-20-2025
- DYN 03-04-2025
- Dividend Yield
- TAC 1.18%
- DYN N/A
- EPS Growth
- TAC N/A
- DYN N/A
- EPS
- TAC 0.38
- DYN N/A
- Revenue
- TAC $2,065,953,587.00
- DYN N/A
- Revenue This Year
- TAC N/A
- DYN N/A
- Revenue Next Year
- TAC N/A
- DYN N/A
- P/E Ratio
- TAC $37.61
- DYN N/A
- Revenue Growth
- TAC N/A
- DYN N/A
- 52 Week Low
- TAC $5.94
- DYN $13.99
- 52 Week High
- TAC $14.64
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- TAC 66.89
- DYN 22.11
- Support Level
- TAC $12.78
- DYN $14.79
- Resistance Level
- TAC $14.60
- DYN $15.90
- Average True Range (ATR)
- TAC 0.49
- DYN 1.50
- MACD
- TAC -0.05
- DYN -0.71
- Stochastic Oscillator
- TAC 91.48
- DYN 4.58
About TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse and growing fleet of electrical power generation assets in Canada, the United States, and Australia. The company has six reportable segments namely, hydro, wind & solar, Energy Marketing, gas, energy transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.